Literature DB >> 8393819

The role of WT1 in Wilms tumorigenesis.

M J Coppes1, C E Campbell, B R Williams.   

Abstract

Genetic alterations in tumor suppressor genes are believed to play an important role in the initiation of childhood and adult malignancies. Tumor-specific loss of heterozygosity for particular chromosomal regions has provided the starting point for the cloning of different tumor suppressor genes, including the Wilms tumor predisposing gene, WT1, at chromosome 11p13. This article reviews the pathology and genetics of Wilms tumor, the cloning of WT1, and the WT1 mutations reported thus far in 15 hereditary and nonhereditary Wilms tumors. The presence of constitutional WT1 mutations in 35 patients with the Denys-Drash syndrome (a syndrome consisting of nephropathy, intersex disorders, and Wilms tumor) is also described. To date, mutations in the WT1 gene have been found in less than 10% of Wilms tumors specimens examined and in greater than 95% of Denys-Drash patients. The possible significance of this observation with regard to both the cellular function of the WT1 protein and the involvement of alternative loci in the development of Wilms tumor is discussed.

Entities:  

Mesh:

Year:  1993        PMID: 8393819     DOI: 10.1096/fasebj.7.10.8393819

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  39 in total

Review 1.  Frasier and Denys-Drash syndromes: different disorders or part of a spectrum?

Authors:  A Koziell; R Grundy
Journal:  Arch Dis Child       Date:  1999-10       Impact factor: 3.791

2.  Molecular basis for modulation of biological function by alternate splicing of the Wilms' tumor suppressor protein.

Authors:  J H Laity; H J Dyson; P E Wright
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-24       Impact factor: 11.205

Review 3.  The possible role and application of WT1 in human leukemia.

Authors:  Z Chen
Journal:  Int J Hematol       Date:  2001-01       Impact factor: 2.490

Review 4.  Wilms' tumor gene WT1: its oncogenic function and clinical application.

Authors:  H Sugiyama
Journal:  Int J Hematol       Date:  2001-02       Impact factor: 2.490

5.  Altered expression of the WT1 wilms tumor suppressor gene in human breast cancer.

Authors:  G B Silberstein; K Van Horn; P Strickland; C T Roberts; C W Daniel
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-22       Impact factor: 11.205

6.  Opposite regulation of estrogen receptor-α and its variant ER-α36 by the Wilms' tumor suppressor WT1.

Authors:  Lianguo Kang; Lei Wang; Zhao-Yi Wang
Journal:  Oncol Lett       Date:  2011-01-21       Impact factor: 2.967

7.  The Wilms' tumor suppressor WT1 induces estrogen-independent growth and anti-estrogen insensitivity in ER-positive breast cancer MCF7 cells.

Authors:  Lei Wang; Zhao-Yi Wang
Journal:  Oncol Rep       Date:  2010-04       Impact factor: 3.906

8.  Regulation of WT1 by phosphorylation: inhibition of DNA binding, alteration of transcriptional activity and cellular translocation.

Authors:  Y Ye; B Raychaudhuri; A Gurney; C E Campbell; B R Williams
Journal:  EMBO J       Date:  1996-10-15       Impact factor: 11.598

9.  Congenital anomalies and genetic disorders in families of children with central nervous system tumours.

Authors:  S M Jones; P C Phillips; P T Molloy; B J Lange; M N Needle; J A Biegel
Journal:  J Med Genet       Date:  1995-08       Impact factor: 6.318

10.  RNA Binding by the KTS Splice Variants of Wilms' Tumor Suppressor Protein WT1.

Authors:  Tadateru Nishikawa; Jonathan M Wojciak; H Jane Dyson; Peter E Wright
Journal:  Biochemistry       Date:  2020-09-29       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.